These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 14755361

  • 1. [The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].
    Tauchert S, Schröder AK, Ortmann O, Diedrich K, Weiss JM.
    Zentralbl Gynakol; 2003 Dec; 125(12):507-14. PubMed ID: 14755361
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Insulin-sensitisers in the treatment of polycystic ovary syndrome.
    Teede HJ, Meyer C, Norman RJ.
    Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Front Horm Res; 2013 Nov; 40():83-102. PubMed ID: 24002407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Revisit of metformin treatment in polycystic ovarian syndrome.
    Lam PM, Cheung LP, Haines C.
    Gynecol Endocrinol; 2004 Jul; 19(1):33-9. PubMed ID: 15625771
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
    Svendsen PF, Nilas L, Nørgaard K, Madsbad S.
    Ugeskr Laeger; 2005 Aug 22; 167(34):3147-51. PubMed ID: 16117910
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk in women with polycystic ovary syndrome.
    Cho LW, Atkin SL.
    Minerva Endocrinol; 2007 Dec 22; 32(4):263-73. PubMed ID: 18091663
    [Abstract] [Full Text] [Related]

  • 14. Insulin resistance, polycystic ovary syndrome and metformin.
    Pugeat M, Ducluzeau PH.
    Drugs; 1999 Dec 22; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
    [Abstract] [Full Text] [Related]

  • 15. Role of metformin in patients with polycystic ovary syndrome: the state of the art.
    Palomba S, Falbo A, Russo T, Orio F, Tollino A, Zullo F.
    Minerva Ginecol; 2008 Feb 22; 60(1):77-82. PubMed ID: 18277354
    [Abstract] [Full Text] [Related]

  • 16. Clinical inquiries. Do insulin-sensitizing drugs increase ovulation rates for women with PCOS?
    Andy C, Flake D, French L.
    J Fam Pract; 2005 Feb 22; 54(2):156, 159-60. PubMed ID: 15689292
    [No Abstract] [Full Text] [Related]

  • 17. Insulin resistance and metformin in polycystic ovary syndrome.
    Ben-Haroush A, Yogev Y, Fisch B.
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug 10; 115(2):125-33. PubMed ID: 15262344
    [Abstract] [Full Text] [Related]

  • 18. Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome.
    Ben Ayed B, Dammak dit Mlik S, Ben Arab H, Trabelssi H, Chahtour H, Mathlouthi N, Dhuib M, Kassis M, Saiidane D, Trabelssi K, Guermazi M.
    Tunis Med; 2009 Jan 10; 87(1):43-9. PubMed ID: 19522426
    [Abstract] [Full Text] [Related]

  • 19. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
    Brettenthaler N, De Geyter C, Huber PR, Keller U.
    J Clin Endocrinol Metab; 2004 Aug 10; 89(8):3835-40. PubMed ID: 15292314
    [Abstract] [Full Text] [Related]

  • 20. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
    Katsiki N, Georgiadou E, Hatzitolios AI.
    Drugs; 2009 Jul 30; 69(11):1417-31. PubMed ID: 19634921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.